Consensus ZyVersa Therapeutics, Inc.

Equities

ZVSA

US98987D3008

Real-time Estimate Cboe BZX Other stock markets 14:49:23 10/06/2024 BST			5-day change	1st Jan Change
4.545 ^USD	+3.06%		-10.73%	-51.00%

05-15	ZyVersa Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
03-25	ZyVersa Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Evolution of the average Target Price on ZyVersa Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

5a6d4da1265297ed5ddcae75dc.2W9rE0Ixqk71_DIcefLxun8uwqgv3vjlbZ8BsbspwAI.7h4_dgdhyD-An1ZFLKS04hd0s-5AjYymGq5U4fkcjHGhMBtccWCSJ7uwXQ~b55aeacfffbd76809ddd9512ba992ce9

Analyst Recommendations on ZyVersa Therapeutics, Inc.

HC Wainwright Cuts Price Target on ZyVersa Therapeutics to $12 From $24, Maintains Buy Rating	03-12	MT
Wall Street Set to Open Flat Friday as Investors Remain Wary of Potential Interest Rate Hike	08/09/23	MT
HC Wainwright Starts ZyVersa Therapeutics With Buy Rating, Price Target is $2.50	08/09/23	MT
ZyVersa Therapeutics, Inc. Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease	15/05/23	CI

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4.41 USD

Average target price

70 USD

Spread / Average Target

+1,487.30%

High Price Target

120 USD

Spread / Highest target

+2,621.09%

Low Price Target

20 USD

Spread / Lowest Target

+353.51%

Consensus detail

Consensus revision (last 18 months)

Analysts covering ZyVersa Therapeutics, Inc.

HC Wainwright

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar